Is lurbinectedin approved for all cancer types?

Is lurbinectedin approved for all cancer types?

Lurbinectedin is approved only for adults with metastatic small cell lung cancer that progressed after platinum-based chemotherapy. The FDA granted accelerated approval in June 2020 for this specific indication.

Why do people ask about broader approval?

Some patients and clinicians look for drugs that cover multiple cancer types because small cell lung cancer is rare and treatment options are limited. Lurbinectedin has been studied in other solid tumors, but none of those studies led to additional FDA approvals.

What clinical trials are still running?

Ongoing trials examine lurbinectedin in ovarian cancer, endometrial cancer, and soft tissue sarcoma. Early-phase results in these areas show some activity, but regulators have not granted approval yet. Results from larger trials will determine whether new indications expand the label.

Can lurbinectedin be used off-label for other cancers?

Physicians may prescribe lurbinectedin outside its approved indication if they determine the patient needs it. Off-label use remains common in oncology, but insurance coverage varies and patients may bear higher costs without an approved indication.

How does lurbinectedin compare with topotecan?

Topotecan is an established second-line treatment for relapsed small cell lung cancer. Lurbinectedin showed higher response rates in a single-arm study than topotecan’s historical data, but no head-to-head comparison with topotecan exists. Kaolin-<|eos|>